The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.
Age 18 years - 55 years
Pregnant patients receiving obstetrical-related care or receiving preconception/fertility care at a WCM-affiliated enrollment site.
Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider
Patients with prior OCS but planned to repeat OCS are eligible
Patients who have previously completed a multigene hereditary cancer syndrome panel
Patients who have a hematologic cancer or hematologic pre-cancer
Patients who have a history of an autologous bone marrow transplant
Weill Medical College of Cornell University
Lead sponsor
Myriad Genetics, Inc.
Collaborator